Assessment of Tanshinone IIA Derivatives for Cardioprotection in Myocardial Ischemic Injury
Planta Medica · 01.07.2025 · 91 (08) · 451-460
DOI: 10.1055/a-2565-8285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.07.2025. Verfasst von Zhiwu Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China. Hauptthemen laut MEDLINE: Abietanes, Cardiotonic Agents, Myocardial Ischemia, Myocardial Infarction. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Double-First-Class University Project.
Abstract (Originalsprache)
Tanshinone ⅡA (TSA), a component of traditional Chinese medicine, effectively protects against myocardial injury. However, its clinical application is limited by poor water solubility and a short half-life. In this study, we report on four TSA derivatives designed and synthesized by our research group. The protective activity against hypoxia-reoxygenation injury in cells was evaluated, and derivative Ⅰ-3 was selected for in vivo experiments to verify its myocardial protective activity in rats with myocardial infarction. The results demonstrated that these four compounds could protect neonatal rat cardiomyocytes from hypoxia-reoxygenation injury. Among the derivatives, Ⅰ-3 showing superior protective effects, we found that Ⅰ-3 has enhanced metabolic stability and an extended half-life. Ⅰ-3 exhibited superior biological activity, effectively reducing the heart infarction area, alleviating myocardial hypertrophy, and enhancing cardiac pumping function. Ⅰ-3 reported in the present work represents a novel and effective derivative of TSA, showing great potential for the treatment of myocardial ischemia (MI).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
- School of Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
ORCID-Profile: Jinxin Wang
Förderung
- National Natural Science Foundation of China
- Double-First-Class University Project
Zitieren
APA
Wu, Z., Xu, Y., Guo, X., Zhang, Z., Wang, J., & Tang, Y. (2025). Assessment of Tanshinone IIA Derivatives for Cardioprotection in Myocardial Ischemic Injury. Planta Medica, 91(08), 451-460. https://doi.org/10.1055/a-2565-8285
Vancouver
Wu Z, Xu Y, Guo X, Zhang Z, Wang J, Tang Y. Assessment of Tanshinone IIA Derivatives for Cardioprotection in Myocardial Ischemic Injury. Planta Medica. 2025;91(08):451-460. doi:10.1055/a-2565-8285
BibTeX
@article{Wu2025,
author = {Wu, Zhiwu and Xu, Ying and Guo, Ximing and Zhang, Zhilan and Wang, Jinxin and Tang, Yiqun},
title = {Assessment of Tanshinone IIA Derivatives for Cardioprotection in Myocardial Ischemic Injury},
journal = {Planta Medica},
year = {2025},
volume = {91},
number = {08},
pages = {451--460},
doi = {10.1055/a-2565-8285}
}
EUVIMED